09:52 AM EST - Canopy Growth Corporation : Said its Spectrum Therapeutics division shared an update on its efforts to develop and commercialize validated cannabis medicines through clinical trials. Demand for cannabinoid-based medicines is emerging around the world. With a highly experienced scientific team and the resources needed to conduct robust clinical trials, Spectrum Therapeutics is pursuing research to introduce products for the therapeutic areas of pain, mood and sleep and to gain access to new markets independent of medical cannabis laws. Canopy Growth Corporation
shares T.WEED are trading down $0.07 at $54.68.
